EquitySector - HealthcareVery High Risk
Regular
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹1,212 Cr
Expense Ratio
2.16%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.93%
+12.48% (Cat Avg.)
3 Years
+19.01%
+18.71% (Cat Avg.)
5 Years
+22.12%
+23.12% (Cat Avg.)
Since Inception
+11.71%
— (Cat Avg.)
Equity | ₹1,159.15 Cr | 95.66% |
Others | ₹52.59 Cr | 4.34% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹140.27 Cr | 11.58% |
Dr Reddy's Laboratories Ltd | Equity | ₹86.99 Cr | 7.18% |
Aurobindo Pharma Ltd | Equity | ₹86.84 Cr | 7.17% |
Lupin Ltd | Equity | ₹74.95 Cr | 6.19% |
Cipla Ltd | Equity | ₹72.49 Cr | 5.98% |
Divi's Laboratories Ltd | Equity | ₹58.55 Cr | 4.83% |
Fortis Healthcare Ltd | Equity | ₹54.74 Cr | 4.52% |
Cash / Net Current Asset | Cash | ₹49.92 Cr | 4.12% |
Zydus Lifesciences Ltd | Equity | ₹45.73 Cr | 3.77% |
Apollo Hospitals Enterprise Ltd | Equity | ₹40.12 Cr | 3.31% |
Wockhardt Ltd | Equity | ₹38.95 Cr | 3.21% |
Alkem Laboratories Ltd | Equity | ₹38.1 Cr | 3.14% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹32.29 Cr | 2.67% |
Laurus Labs Ltd | Equity | ₹29.49 Cr | 2.43% |
HealthCare Global Enterprises Ltd | Equity | ₹28.97 Cr | 2.39% |
Ajanta Pharma Ltd | Equity | ₹25.53 Cr | 2.11% |
Orchid Pharma Ltd | Equity | ₹24.73 Cr | 2.04% |
Medi Assist Healthcare Services Ltd | Equity | ₹24.12 Cr | 1.99% |
Torrent Pharmaceuticals Ltd | Equity | ₹23.18 Cr | 1.91% |
FDC Ltd | Equity | ₹22.15 Cr | 1.83% |
Ipca Laboratories Ltd | Equity | ₹20.56 Cr | 1.70% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.33 Cr | 1.43% |
Dr. Lal PathLabs Ltd | Equity | ₹17.12 Cr | 1.41% |
Indoco Remedies Ltd | Equity | ₹16.67 Cr | 1.38% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹14.58 Cr | 1.20% |
Piramal Pharma Ltd | Equity | ₹13.9 Cr | 1.15% |
Ami Organics Ltd | Equity | ₹11.93 Cr | 0.98% |
Coromandel International Ltd | Equity | ₹10.86 Cr | 0.90% |
Sanofi India Ltd | Equity | ₹10.59 Cr | 0.87% |
Mankind Pharma Ltd | Equity | ₹10.09 Cr | 0.83% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹8.98 Cr | 0.74% |
Procter & Gamble Health Ltd | Equity | ₹8.61 Cr | 0.71% |
Medplus Health Services Ltd | Equity | ₹8.59 Cr | 0.71% |
Metropolis Healthcare Ltd | Equity | ₹8.08 Cr | 0.67% |
Dr Agarwal’s Health Care Ltd | Equity | ₹8 Cr | 0.66% |
Syngene International Ltd | Equity | ₹7.99 Cr | 0.66% |
Inventurus Knowledge Solutions Ltd | Equity | ₹7.35 Cr | 0.61% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹4.86 Cr | 0.40% |
Deepak Nitrite Ltd | Equity | ₹4.16 Cr | 0.34% |
A) Repo | Cash - Repurchase Agreement | ₹2.67 Cr | 0.22% |
Laxmi Dental Ltd | Equity | ₹0.71 Cr | 0.06% |
Large Cap Stocks
35.26%
Mid Cap Stocks
31.87%
Small Cap Stocks
27.82%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,132.2 Cr | 93.44% |
Basic Materials | ₹26.95 Cr | 2.22% |
Standard Deviation
This fund
15.47%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.87
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since March 2021
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.16% | Exit Load No Charges | Fund Size ₹1,212 Cr | Age 9 years 1 month | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,88,905 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹1,212 Cr
Expense Ratio
2.16%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.93%
+12.48% (Cat Avg.)
3 Years
+19.01%
+18.71% (Cat Avg.)
5 Years
+22.12%
+23.12% (Cat Avg.)
Since Inception
+11.71%
— (Cat Avg.)
Equity | ₹1,159.15 Cr | 95.66% |
Others | ₹52.59 Cr | 4.34% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹140.27 Cr | 11.58% |
Dr Reddy's Laboratories Ltd | Equity | ₹86.99 Cr | 7.18% |
Aurobindo Pharma Ltd | Equity | ₹86.84 Cr | 7.17% |
Lupin Ltd | Equity | ₹74.95 Cr | 6.19% |
Cipla Ltd | Equity | ₹72.49 Cr | 5.98% |
Divi's Laboratories Ltd | Equity | ₹58.55 Cr | 4.83% |
Fortis Healthcare Ltd | Equity | ₹54.74 Cr | 4.52% |
Cash / Net Current Asset | Cash | ₹49.92 Cr | 4.12% |
Zydus Lifesciences Ltd | Equity | ₹45.73 Cr | 3.77% |
Apollo Hospitals Enterprise Ltd | Equity | ₹40.12 Cr | 3.31% |
Wockhardt Ltd | Equity | ₹38.95 Cr | 3.21% |
Alkem Laboratories Ltd | Equity | ₹38.1 Cr | 3.14% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹32.29 Cr | 2.67% |
Laurus Labs Ltd | Equity | ₹29.49 Cr | 2.43% |
HealthCare Global Enterprises Ltd | Equity | ₹28.97 Cr | 2.39% |
Ajanta Pharma Ltd | Equity | ₹25.53 Cr | 2.11% |
Orchid Pharma Ltd | Equity | ₹24.73 Cr | 2.04% |
Medi Assist Healthcare Services Ltd | Equity | ₹24.12 Cr | 1.99% |
Torrent Pharmaceuticals Ltd | Equity | ₹23.18 Cr | 1.91% |
FDC Ltd | Equity | ₹22.15 Cr | 1.83% |
Ipca Laboratories Ltd | Equity | ₹20.56 Cr | 1.70% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.33 Cr | 1.43% |
Dr. Lal PathLabs Ltd | Equity | ₹17.12 Cr | 1.41% |
Indoco Remedies Ltd | Equity | ₹16.67 Cr | 1.38% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹14.58 Cr | 1.20% |
Piramal Pharma Ltd | Equity | ₹13.9 Cr | 1.15% |
Ami Organics Ltd | Equity | ₹11.93 Cr | 0.98% |
Coromandel International Ltd | Equity | ₹10.86 Cr | 0.90% |
Sanofi India Ltd | Equity | ₹10.59 Cr | 0.87% |
Mankind Pharma Ltd | Equity | ₹10.09 Cr | 0.83% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹8.98 Cr | 0.74% |
Procter & Gamble Health Ltd | Equity | ₹8.61 Cr | 0.71% |
Medplus Health Services Ltd | Equity | ₹8.59 Cr | 0.71% |
Metropolis Healthcare Ltd | Equity | ₹8.08 Cr | 0.67% |
Dr Agarwal’s Health Care Ltd | Equity | ₹8 Cr | 0.66% |
Syngene International Ltd | Equity | ₹7.99 Cr | 0.66% |
Inventurus Knowledge Solutions Ltd | Equity | ₹7.35 Cr | 0.61% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹4.86 Cr | 0.40% |
Deepak Nitrite Ltd | Equity | ₹4.16 Cr | 0.34% |
A) Repo | Cash - Repurchase Agreement | ₹2.67 Cr | 0.22% |
Laxmi Dental Ltd | Equity | ₹0.71 Cr | 0.06% |
Large Cap Stocks
35.26%
Mid Cap Stocks
31.87%
Small Cap Stocks
27.82%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,132.2 Cr | 93.44% |
Basic Materials | ₹26.95 Cr | 2.22% |
Standard Deviation
This fund
15.47%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.87
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since March 2021
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.16% | Exit Load No Charges | Fund Size ₹1,212 Cr | Age 9 years 1 month | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,88,905 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments